Company Analysis Applied Molecular Transport Inc.
1. Summary
Advantages
- Price (0.263 $) is less than fair price (0.3066 $)
- The stock's return over the last year (0%) is higher than the sector average (-48.08%).
Disadvantages
- Dividends (0%) are below the sector average (0.5339%).
- Current debt level 33.61% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-111.78%) is lower than the sector average (ROE=103.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Applied Molecular Transport Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -35.1% | 0.3% |
| 90 days | 0% | -48.6% | 6.9% |
| 1 year | 0% | -48.1% | 18.1% |
AMTI vs Sector: Applied Molecular Transport Inc. has outperformed the "Healthcare" sector by 48.08% over the past year.
AMTI vs Market: Applied Molecular Transport Inc. has significantly underperformed the market by -18.14% over the past year.
Stable price: AMTI is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AMTI with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.263 $) is lower than the fair price (0.3066 $).
Price not significantly lower than the fair price: The current price (0.263 $) is slightly lower than the fair price by 16.6%.
5.2. P/E
P/E vs Sector: The company's P/E (0) is higher than that of the sector as a whole (-274.25).
P/E vs Market: The company's P/E (0) is higher than that of the market as a whole (-80.5).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.2385) is lower than that of the sector as a whole (256.7).
P/BV vs Market: The company's P/BV (0.2385) is lower than that of the market as a whole (51.89).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (56.99).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (137.42).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.0826) is lower than that of the sector as a whole (12.51).
EV/Ebitda vs Market: The company's EV/Ebitda (0.0826) is higher than that of the market as a whole (-47.95).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 18.82% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (18.82%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-22.73%).
6.4. ROE
ROE vs Sector: The company's ROE (-111.78%) is lower than that of the sector as a whole (103.63%).
ROE vs Market: The company's ROE (-111.78%) is lower than that of the market as a whole (-10.25%).
6.6. ROA
ROA vs Sector: The company's ROA (-78.03%) is lower than that of the sector as a whole (-2.84%).
ROA vs Market: The company's ROA (-78.03%) is lower than that of the market as a whole (39.65%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-85.16%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-85.16%) is lower than that of the market as a whole (8.73%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5339%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 01.09.2022 | Cross Shawn President & COO |
Sale | 1.42 | 1 255 | 884 |
| 01.09.2022 | Hants Brandon CFO |
Sale | 1.42 | 656 | 462 |
| 01.09.2022 | Kanwar Bittoo Chief Medical Officer |
Sale | 1.42 | 714 | 503 |
| 01.09.2022 | Mahmood Tahir Ph.D. Chief Executive Officer |
Sale | 1.42 | 2 447 | 1 723 |
| 01.09.2022 | Mrsny Randall Ph.D. Director |
Sale | 1.42 | 574 | 404 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
